TY - T1的纵向变化定量脊髓多发性硬化患者的MRI: 5年的一项研究的结果(S47.001) JF -神经学乔-神经学六世- 90 - 15补充Jiwon哦SP - S47.001盟盟——Kateryna Cybulsky AU - Min陈盟Suradech Suthipho首页suwan AU -埃斯特尔Seyman AU -亚伦Carass AU -玛丽Diener-West AU - Peter van Zijl盟杰里王子AU -丹尼尔帝国AU -彼得·卡拉布雷西Y1 - 2018/04/10 UR - //www.ez-admanager.com/content/90/15_Supplement/S47.001.abstract N2 -目的:评估脊髓(SC) MRI定量措施5年来,和描述之间的关系变化与临床定量SC-MRI残疾。背景:之前的研究已经表明,量化SC-MRI措施与医学相关临床残疾,但纵向变化的评价量化SC-MRI女士是有限的。设计/方法:75 MS患者接受3 t SC-MRI和临床评估(扩大残疾状态量表(eds))在基线,2和5年。感兴趣的限定轴SC横截面积(CSA)同样被用来获得:CSA,分数各向异性(FA),意思是,垂直,平行扩散系数(医学博士,λ⊥,λ| |,)和magnetization-transfer-ratio(地铁)。Mixed-effects回归将科目的拦截和斜坡是用来评估纵向变化SC-MRI措施。皮尔森系数(r)评估科目的斜坡和后续eds分数之间的关系。结果:SC-CSA和地铁减少,而医学增加(p = 0.009, p = 0.03, p = 0.09)在5.7年的随访期间。有比较强烈的个人SC-MRI与斜坡之间的相关性指数和后续eds分数2和5年(2年:r与FA =−0.23(术中,0.001);MD = 0.28(术中,0.001);λ⊥= 0.32(术中,0.001);λ| | = 0.13 (p = 0.01),地铁=−0.29(术中,0.001);SC-CSA =−0.50(术中,0.001);5年与FA =−0.23 r(术中,0.001);MD = 0.31(术中;0.001);λ⊥= 0.34(术中,0.001);λ| | =−0.12 (p = 0.05),地铁=−0.37(术中,0.001);SC-CSA =−0.47(术中;0.001)]。个人与利率变化的FA,λ⊥,λ| |,地铁和SC-CSA大幅高于研究样本均值显示更强的相关性与后续临床措施。2年和5年特殊斜坡有紧密的关联(r = 0.93和0.96 SC-CSA和地铁)。Conclusions: In MS, changes in quantitative SC-MRI indices are measurable over 5 years, likely reflecting ongoing pathological processes. Of clinical relevance is that subject-specific trajectories of SC-MRI index changes at both 2 and 5 years are highly relevant to disability at follow-up, and subject-specific trajectories at 2 and 5 years are strongly correlated. These findings suggest that individual dynamics of change should be compared to average values when interpreting longitudinal SC-MRI measures, and that measuring short-term change is predictive of long-term clinical disability, which could expand the clinical utility of these techniques.Study Supported by: National MS Society, MS Society of CanadaDisclosure: Dr. Oh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EMD-Serono, Novartis, Biogen-Idec, Sanofi-Genzyme, Roche, Teva. Dr. Oh has received research support from Biogen-Idec. Dr. Cybulsky has nothing to disclose. Dr. Chen has nothing to disclose. Dr. Suthiphosuwan has nothing to disclose. Dr. Seyman has nothing to disclose. Dr. Carass has nothing to disclose. Dr. Diener-West has nothing to disclose. Dr. Van Zijl has nothing to disclose. Dr. Prince has nothing to disclose. Dr. Reich has nothing to disclose. Dr. Calabresi has nothing to disclose. ER -